Consistently, neutralizing IL-6 activity decreased CAF-CM-induced survivin expression in pancreatic cancer cells, whereas treatment of cancer cells with recombinant IL-6 increased it, mimicking CAF-CM effects (Fig6G–H). Here, BIRC5 is linked to cancer.